BioHarvest Sciences (BHSC.C) has officially begun direct-to-consumer sales of VINIA®, the Company’s flagship product, in the Unites States, via its VINIA® website.
“This major event is the culmination of over 12 years of extensive R&D”…it is the realization of our vision to bring science-based nutraceuticals, with clinically proven benefits, to consumers. Today is validation of the efforts of the R&D team that has relentlessly pursued the development of the BioFarming technology and VINIA®. Most of the team have been with the Company for 12 years and are not only celebrating the culmination of their efforts in such a momentous event but are actively applying the BioFarming platform to the development of new products, including new cannabis-based products,” said Dr. Yochi Hagay, CTO of BioHarvest.
The release of BioHarvest’s VINIA® dietary supplement in the United States has been in the oven for quite some time. Based off of BioFarming technology, the Company was able to create VINIA®, the first and only product in the world containing Piceid Resveratrol from red grapes at levels in each 400mg VINIA® capsule equivalent to an average bottle of red wine. Put simply, VINIA® provides the full health benefits of an entire bottle of wine without the alcohol, calories, and sugar. Moreover, the bioavailability of VINIA® is exceptional, entering the blood stream in 20 minutes and providing 12 hours of sustained release. With this in mind, VINIA® is intended to promote heart health, improve physical energy, and increase mental alertness by increasing blood flow and the delivery of oxygen throughout the body.
VINIA® is undeniably a unique formulation with the potential to stand out in the United States’ $53 billion dietary supplements market. However, the success of VINIA® will largely depend on BioHarvest’s ability to market and advertise their flagship product. With that being said, the Company has already recognized this and has allocated significant budget to drive awareness regarding the unique properties of VINIA®.
In particular, BioHarvest intends to target consumers aged 40 and above via all major social platforms including Facebook, YouTube, Google and other online channels such as Taboola, a private advertising company. In addition to social media platforms, the Company also plans to launch an extensive public relations campaign targeting this demographic of consumers. The first phase of this launch will focus on the scientific credentials of VINIA®, communicating its superiority over other supplements.
I focused the efforts and resources of the Company on building a commercial platform and manufacturing capabilities in order to bring the BioFarming based products to the market in an efficient and ultimately profitable way. We initially launched our products in Israel, so that we could test our capabilities. The success we are experiencing in Israel can be a predictor for the US market. I am optimistic about the sales of VINIA® in the US and intend to provide revenue guidance by mid-July 2021,” said Ilan Sobel, CEO of BioHarvest.
Leading up to the launch of VINIA® in the United States, BioHarvest’s performance has been commendable. Every move that Bioharvest has made has served a purpose, allowing the Company to dominate in the Israeli market and reach record breaking sales. Even now, the Company has made the necessary preparations to ensure VINIA® gets the exposure it needs to excel in United States’ lucrative dietary supplements market. However, all we can do now is wait and see if VINIA® earns its spot as the Gold Standard in the nutraceuticals market. As VINIA® sales proceed today, BioHarvest is definitely worth keeping an eye on.
BioHarvest’s share price opened at $0.375, up from a previous close of $0.365. The Company’s shares are up 2.74% and are currently trading at $0.375 as of 11:39AM ET. This indicates that there has been some change following the news.